Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.74 |
| ▸ | CA1 | P00915 | 1/20 | 0.74 |
| ▸ | CA2 | P00918 | 1/20 | 0.74 |
| ▸ | CA7 | P43166 | 1/20 | 0.74 |
| ▸ | CA9 | Q16790 | 1/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822596 | 1.00 | CA12 (0.74) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL30822580 | 0.98 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5597547 | 0.98 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28129617 | 0.98 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27877492 | 0.86 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| 2,6-Dimethoxybenzoic Acid SCHEMBL149926 | 0.86 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30313283 | 0.85 | CA9 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1957640 | 0.85 | CA9 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27873369 | 0.84 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| 2,6-Dimethoxybenzoic Acid SCHEMBL7867072 | 0.84 | CA12 (0.95) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-106365978-B | A kind of preparation method of the fluoro- 6- methoxy benzoic acid of 2,3- bis- | 绍兴上虞华伦化工有限公司 | 2019-01-11 | — | — | CN | claimed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| CN-106365978-A | Preparation method for 2, 3-difluoro-6-methoxy benzoic acid | 绍兴上虞华伦化工有限公司 | 2017-02-01 | — | — | CN | claimed |
| CN-105523921-A | Method for preparing 2,3-difluoro-6-methoxybenzoic acid | TIANJIN HEOWNS BIOCHEMISTRY TECH CO LTD | 2016-04-27 | — | — | CN | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| CN-1299365-A | Hygromycin A derivatives | PFIZER PROD INC (US) | 2001-06-13 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1075483-A2 | HYGROMYCIN A DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | CA12 1832/4885CA1 2402/4885CA2 1446/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CA12 4858/4885CA1 4872/4885CA2 4701/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | CA12 3421/4885CA1 2502/4885CA2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.